A Phase 3 interventional study of SAB-142 and Placebo in Type 1 Diabetes (T1D), sponsored by University of Florida. Recruiting at 4 sites in United States. Open to participants aged 5 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by University of Florida · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Diabetes Mellitus, Type 1 by University of Florida — 3 open to participants now, 3 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · University of Florida.
Among the 18 studies in Diabetes Mellitus, Type 1 by University of Florida, this one is the 2nd largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 3, and was the 18th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →3 of the 18 studies in Diabetes Mellitus, Type 1 by University of Florida are open now, in 1 country. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 4–35
University of Florida · Sites in United States
Ages 0–100 · Healthy volunteers
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 5 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 1
First in 2005; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 108 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 38 across the 14 interventional studies, 373 across the 4 observational. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Florida is the lead sponsor of 1,290 studies on the registry; 202 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Diabetes Mellitus, Type 1 by University of Florida, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 3, multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety, and tolerability of SAB-142, a fully human anti-thymocyte globulin (h-ATG), in participants aged 5 to 40 years with Stage 3 type 1 diabetes (T1D). The study will enroll participants with recent-onset T1D (>100 days to \<1 year from diagnosis) and established-onset T1D (≥1 year to ≤2 years from diagnosis) who retain residual beta-cell function as demonstrated by stimulated C-peptide levels >0.2 nmol/L. Participants will be randomized in a 2:1 ratio to receive SAB-142 or placebo in addition to standard diabetes care. The primary objective is to determine whether SAB-142 preserves beta-cell function over 12 months as measured by stimulated C-peptide response during a mixed meal tolerance test (MMTT). External data from the SAB-142-201 SAFEGUARD study will be incorporated to include participants with new-onset T1D (\<100 days from diagnosis) in the primary efficacy analysis.
Type 1 diabetes is an autoimmune disease characterized by progressive destruction of pancreatic beta cells. SAB-142 is a purified fully human multi-specific anti-thymocyte globulin designed to modulate autoimmune responses while potentially avoiding some of the immunogenicity and adverse effects associated with rabbit-derived anti-thymocyte globulin preparations. This study will evaluate whether SAB-142 preserves endogenous insulin production and improves clinical outcomes in participants with Stage 3 T1D who have residual beta-cell function.
The study consists of three disease-duration cohorts:
Cohort 1: New-onset T1D (\<100 days from diagnosis; external data from SAB-142-201 SAFEGUARD) Cohort 2: Recent-onset T1D (>100 days to \<365 days from diagnosis) Cohort 3: Established-onset T1D (365 to 730 days from diagnosis)
Approximately 72 participants will be enrolled into Cohorts 2 and 3 and randomized 2:1 to SAB-142 or placebo. An additional 36 age-matched participants from SAB-142-201 SAFEGUARD will comprise Cohort 1, resulting in a combined efficacy dataset of approximately 108 participants. Participants will receive an induction treatment period at baseline and a maintenance treatment period at Month 6. Follow-up continues through Month 12.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Males and females 5-40 years old*, inclusive, at the time of randomisation.
* Note: Age step-down rules apply, as described in protocol Section 6.1.
Participant has received a diagnosis of T1D according to American Diabetes Association criteria (refer Section 22.1) as following:
Note: Unless previously diagnosed with preclinical (Stage 1 or Stage 2 T1D), participant must have initiated insulin therapy the time of randomisation.
Participant has a positive result on testing for at least one of the following T1D-related autoantibodies during screening:
Female participants:
i.Have a negative result on a serum (beta human chorionic gonadotropin [β-hCG]) at screening and a negative urine β-hCG pregnancy test prior to study drug administration on Day 1 of both treatment periods.
ii.Agree not to become pregnant or donate ova from the time of signing the consent form until the end of the study visit.
iii.If not exclusively in a same-sex relationship or abstinent as a committed lifestyle, must agree to use adequate (which is defined as use of a condom by the male partner combined with use of a highly effective method of contraception [Section 11.3.1]) from the time of signing the consent and for the duration of the study.
* Note: Female participants will be considered to be pre-pubertal (and of nonchildbearing potential) if they have not yet started menstruation. This should also be verified by the parent(s)/guardian(s). If a female participant reaches menarche during the study, then she is to be considered as a woman of childbearing potential from that time forwards, and contraceptive requirements will apply.
Male participants, if not biologically or surgically sterilised, must:
Exclusion Criteria:
An individual has any of the following haematologic parameters, confirmed by repeat tests, during Screening:
Note: Specific haematologic, oncologic or other systemic conditions that might otherwise result in exclusion and/or is heretofore unrecognised should be considered in individuals who have one or more blood cell counts below or above the references ranges.
Recent or planned vaccinations as follows:
Countries within the EU member states only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SAB-142 in recent and established onset T1D
Drug: SAB-142
Placebo Comparator
Drug: Placebo
Treatment Period 1 (Induction) Day 1: SAB-142 0.5 mg/kg IV Day 2: SAB-142 2.0 mg/kg IV Treatment Period 2 (Month 6 Maintenance) Day 1: SAB-142 0.5 mg/kg IV Day 2: SAB-142 1.0 mg/kg IV Total induction dose: 2.5 mg/kg Total maintenance dose: 1.5 mg/kg
Placebo Comparator: Placebo
Area under the concentration-time curve (AUC) of C-peptide after a 2 hour mixed meal tolerance test (MMTT)
This is a measure of endogenous insulin production and β cell function (change from baseline in C-peptide ln \[AUC+1\].
Time frame: Dose administration to 12 Months
AUC of C-peptide after a 2-hour MMTT in a priori in vitro identified "responders" and "non-responders"
This is achange from baseline in C--peptide ln \[AUC+1\] at 12 months) in a priori in vitro identified "responders" and "non-responders" to SAB-142 and compared to placebo.
Time frame: Baseline, Months 3, 6, 9 and 12
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0
Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs).
Time frame: Dose administration to 12 Months
To evaluate the pharmacokinetics (PK) of SAB-142
Evaluate SAB-142 serum concentrations over the infusion
Time frame: Days 1 and 2 of each treatment period (pre- and post-dose/end of infusion [EOI]), plus Week 1 for TP1 (for participants that attend the optional in-clinic visit), Week 4, and Months 3, and 7.
To evaluate the immunogenicity of SAB-142
Incidence and titres of anti-SAB-142 antibodies in serum including neutralising antibodies (nAbs) if indicated.
Time frame: Baseline, Week 1 (for participants that attend the optional in-clinic visit), Week 4, Months 3, 6, 7, 9, and 12.
Immunophenotyping following SAB-142 administration will be performed on PBMC using flowcytometry
Changes in immune cell populations following SAB-142 administration will be performed on PBMC using flowcytometry. All data will be reported as a percentage of lymphocytes and compared to baseline analysis. Populations to be tested: * CD3+CD4+ Tcells * CD3+CD8+ Tcells * CD19+ Bcells
Time frame: Baseline (Day 1, pre-dose), Week 4, Months 3, 6, 7, 9 and 12.
Haemoglobin A1c (HbA1c) levels
Hba1c is a key clinical parameter for looking at improvement in type 1 diabetes .Expressed in % and mmol/molmanagement
Time frame: Baseline, Months 3, 6, 9 and 12
Time in Range (TIR)
Expressed as a daily average of the percentage of time in a 24-hour day a participant's CGM reading is \>70 but ≤180 mg/dL (\>3.9 to ≤10.0 mmol/L), assessed by CGM
Time frame: Baseline, Months 3, 6, 9 and 12
Improvement in Time in Tight Range (TITR)
Expressed as a daily average of the percentage of time in a 24hour day a participant's glucose is \>70 but ≤140 mg/dL (\>3.9 to ≤7.8 mmol/L), assessed using continuous glucose monitoring (CGM)
Time frame: Baseline, Months 3, 6, 9 and 12
Improvement in Time Below Range on a Continuous Glucose Monitor
Time Below Range on a continuous glucose monitor is a key clinical indicator for improvement in type 1 diabetes management
Time frame: Baseline, Months 3, 6, 9 and 12
Improvement in Time Above Range on a Continuous Glucose Monitor
Time Above Range on a continuous glucose monitor is a key clinical indicator for improvement in type 1 diabetes management
Time frame: Baseline, Months 3, 6, 9 and 12
Number of clinically important hypoglycemic episodes
Defined as the total number of Level 2 and 3 hypoglycaemic events and/or episodes of cognitive impairment requiring external assistance for recovery (participant's diary and CGM-based).
Time frame: Baseline, Months 3, 6, 9 and 12
Exogenous Insulin use
Defined as a daily average in units per kilogram per day (U/kg/day) (total daily insulin based on participant's diary at predefined study periods).
Time frame: Baseline, Months 3, 6, 9 and 12
Proportion of participants with partial clinical remission
Defined as an insulin requirement of \<0.25 units per kg of body weight per day and HbA1c \<6.5% (47 mmol/mol).
Time frame: Baseline, Months 3, 6, 9 and 12
Proportion of participants with partial remission
Defined as insulin-dose adjusted A1c (IDAA1c) + \[4 × insulin dose (units per kilogram per 24 h) ≤9
Time frame: Baseline, Months 3, 6, 9 and 12
Total BETA-2 score
A score comprised of fasting plasma glucose (mmol/L), HbA1c (%), daily insulin (U/kg), and fasting C-peptide (nmol/L)
Time frame: Baseline, Months 3, 6, 9 and 12
Insulin dose-adjusted A1c (IDAA1C)
Time frame: Baseline, Months 3, 6, 9 and 12
C-peptide quantitative response (QR) metric
Time frame: Baseline, Months 3, 6, and 12.
2-hour MMTT C-peptide AUC
Time frame: Baseline, Months 3, 6, and 12.
Fasting C-peptide
Time frame: Baseline, Months 3, 6, 9, and 12.
Proportion of participants maintaining a clinically significant stimulated peak C-peptide of ≥0.2 nmol/L during the 2-hour MMTTs
Time frame: Baseline, Months 3, 6, and 12.
Fasting proinsulin-to-C-peptide ratio, a measure of β cell endoplasmic reticulum stress and dysfunction
Time frame: Baseline, Months 3, 6, 9, and 12.
Calculated estimated residual stimulated C-peptide (CPEST)
Time frame: Baseline, Months 3, 6, 9, and 12.
Proportion of participants with poor glycaemic control, defined as HbA1c of ≥9%
Time frame: Baseline, Months 3, 6, 9, and 12.
The number of participants who do not require exogenous insulin because they are able to achieve local, regional, or national age-based glycaemic management goals for HbA1c and/or routine blood glucose levels
Time frame: Baseline, Months 3, 6, 9, and 12.
Incidence of Level 1, 2, and Level 3 hypoglycaemia during the CGM reporting periods
Time frame: Baseline, Months 3, 6, 9 and 12
Incidence of diabetic ketoacidosis requiring medical attention
Incidence of diabetic ketoacidosis requiring medical attention, defined as a hyperglycaemic episode with serum or urine ketones elevated beyond upper limit of normal along with serum bicarbonate ≤18 mmol/L or blood pH ≤7.3, or both, and resulting in outpatient, emergency room visit or hospitalisation
Time frame: Baseline, Months 3, 6, 9 and 12
Participants with both HbA1c and exogenous insulin doses in range
Participants with both HbA1c in the American Diabetes Association target range (i.e., \<7.5%) and exogenous insulin dose in specific ranges (\<0.25, 0.25 to \<0.50, 0.50 to \<0.75, 0.75 to \<1.0, 1.0 to \<1.25, and ≥1.25 U/kg/day)
Time frame: Baseline, Months 3, 6, 9, and 12.
Patient- and parent-reported outcomes (PROs)
Patient-reported outcomes: oAge-appropriate Diabetes Treatment Satisfaction Questionnaire (DTSQ) o Age-appropriate PedsQL TM Diabetes Module Version 3.2 o Parent reports for DTSQ (to be completed by caregivers \[if available\]) of participants \<18 years old
Time frame: Baseline, Months 6 and 12
Changes in serum cytokine IL-2
Changes in serum cytokine IL-2 reported in pg/mL
Time frame: Day 1 (pre-dose), Day 2 (EOI), and Week 4.
Changes in serum cytokine IL-4
Changes in serum cytokine IL-4 reported in pg/mL
Time frame: Day 1 (pre-dose), Day 2 (EOI), and Week 4.
Changes in serum cytokine IL-6
Changes in serum cytokine IL-6 reported in pg/mL
Time frame: Day 1 (pre-dose), Day 2 (EOI), and Week 4.
Changes in serum cytokine IL-10
Changes in serum cytokine IL-10 reported in pg/mL
Time frame: Day 1 (pre-dose), Day 2 (EOI), and Week 4.
Changes in serum cytokine IL-12
Changes in serum cytokine IL-12 reported in pg/mL
Time frame: Day 1 (pre-dose), Day 2 (EOI), and Week 4.
Changes in serum cytokine IL-17A
Changes in serum cytokine IL-17A reported in pg/mL
Time frame: Day 1 (pre-dose), Day 2 (EOI), and Week 4.
Ex vivo safety immune functional assay: ELIspot Assay based on the PBMC samples
This assay is a sensitive, quantitative method used to assess PBMC function to release cytokines following administration of an investigational drug by measuring antigen-specific cytokine secretion at the single-cell level. PBMCs collected at defined timepoints (e.g., pre- and post-dose) are stimulated ex vivo, and IFN-γ or IL-13 cytokines released by activated cells are captured on antibody-coated plates, forming spots that correspond to individual responsive cells (reported as spot-forming units). Changes in spot frequency and cytokine profile relative to baseline provide a functional readout of drug effect, enabling evaluation of immune activation, suppression, or polarization, and supporting pharmacodynamic, dose-response, and mechanism-of-action assessments in clinical studies.
Time frame: Baseline, and Months 3, 6, 9, and 12
Immune assays 1
Functional exhaustion assay oActivation induced marker (AIM) assay
Time frame: Baseline, Week 4, Months 6 and 12
Neutrophil assay
Time frame: Baseline, Months 6 and 9
PBMCs
Ex vivo treatment of pre-dose peripheral blood mononuclear cells (PBMCs)
Time frame: Baseline
IPT
Whole blood sample for IPT
Time frame: Baseline, Week 4, Month 3, Month 6, Month 7, Month 9, and Month 12.
Single nucleotide polymorphism (SNP) analysis
Single Nucleotide Polymorphism analysis will be reported as a genetic marker profile of T1D risk variants to to potentially identify treatment responders and non-responders post-hoc.
Time frame: Baseline
DNA methylation and RNA-sequencing
DNA methylation will be reported as an epigenetic profile to potentially identify treatment responders and non-responders post-hoc. RNA-sequencing will be reported as a longitudinal profile of single cell immune transcriptome changes over time to potentially identify treatment responders and non-responders post-hoc.
Time frame: Baseline, Months 6 and 9
microRNA expression
Clinical serum samples will be collected according to the SAB-142-201 protocol and Laboratory Manual. The data will reported as a risk profile of miRNAs will be used to explore predictivity of responder or non-responder outcomes.
Time frame: Baseline, Months 3, 6 and 9
Started Nov 2026 (actual). Primary completion is estimated for Mar 2029, 27 months after the start.
Of 108 phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's planned 27 months is above that.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.